Patients who had Response Evaluation Criteria In Solid Tumors-defined PD who were participating in 3 prospective trials of first-line erlotinib in advanced lung cancer were studied retrospectively , and the progression characteristics were compared between patients with and without EGFR-sensitizing mutations .